



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

# PRODUCT INFORMATION




**BPN14770**

Item No. 34075

**CAS Registry No.:** 1606974-33-7  
**Formal Name:** 4-[[2-(3-chlorophenyl)-6-(trifluoromethyl)-4-pyridinyl]methyl]-benzeneacetic acid

**Synonym:** Zatomilast  
**MF:** C<sub>21</sub>H<sub>15</sub>ClF<sub>3</sub>NO<sub>2</sub>  
**FW:** 405.8  
**Purity:** ≥98%  
**Supplied as:** A solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

## Laboratory Procedures

BPN14770 is supplied as a solid. A stock solution may be made by dissolving the BPN14770 in the solvent of choice, which should be purged with an inert gas. BPN14770 is soluble in methanol.

## Description

BPN14770 is an inhibitor of phosphodiesterase 4D (PDE4D).<sup>1</sup> It selectively inhibits dimeric PDE4D<sup>S129D</sup> and PDE4D<sup>S54D</sup>, which mimic the phosphorylated, activated forms of PDE4D, over wild-type dimeric PDE4D, dimeric PDE4D<sup>S133D</sup>, and monomeric PDE4D2 (IC<sub>50</sub>s = 7.8, 7.4, 1,018, 2,013, and 127 nM, respectively). BPN14770 (0.3-30 mg/kg) enhances novel object discrimination in mice. It decreases hyperarousal and increases social interaction time, indicating anxiolytic-like activity, nesting, and marble-burying behavior in the *Fmr1*<sup>-/-</sup> mouse model of fragile X syndrome when administered at a dose of 0.3 mg/kg.<sup>2</sup>

## References

1. Gurney, M.E., Nugent, R.A., Mo, X., *et al.* Design and synthesis of selective phosphodiesterase 4D (PDE4D) allosteric inhibitors for the treatment of Fragile X Syndrome and other brain disorders. *J. Med. Chem.* **62**(10), 4884-4901 (2019).
2. Gurney, M.E., Cogram, P., Deacon, R.M., *et al.* Multiple Behavior Phenotypes of the Fragile-X Syndrome Mouse Model Respond to Chronic Inhibition of Phosphodiesterase-4D (PDE4D). *Sci. Rep.* **7**(1), 14653 (2017).

### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/13/2023

## CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM